These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. SNPs in ERCC1 and drug response to cisplatin in non-small-cell lung cancer patients. Osawa K Pharmacogenomics; 2011 Apr; 12(4):445-7. PubMed ID: 21521014 [No Abstract] [Full Text] [Related]
5. Pharmacogenomics in non-small-cell lung cancer chemotherapy. Danesi R; Pasqualetti G; Giovannetti E; Crea F; Altavilla G; Del Tacca M; Rosell R Adv Drug Deliv Rev; 2009 May; 61(5):408-17. PubMed ID: 19292993 [TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Danesi R; de Braud F; Fogli S; de Pas TM; Di Paolo A; Curigliano G; Del Tacca M Pharmacol Rev; 2003 Mar; 55(1):57-103. PubMed ID: 12615954 [TBL] [Abstract][Full Text] [Related]
8. Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays. Kani K; Sordella R; Mallick P Methods Mol Biol; 2012; 795():233-53. PubMed ID: 21960227 [TBL] [Abstract][Full Text] [Related]
9. The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Dowell JE; Minna JD Nat Clin Pract Oncol; 2004 Nov; 1(1):2-3. PubMed ID: 16264773 [No Abstract] [Full Text] [Related]
10. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. Shih JY; Gow CH; Yang PC N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893 [No Abstract] [Full Text] [Related]
11. Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies. Joshi VA; Kucherlapati R Pharmacogenomics; 2007 Sep; 8(9):1211-20. PubMed ID: 17924836 [TBL] [Abstract][Full Text] [Related]
12. Irinogenetics: what is the right star? Innocenti F; Vokes EE; Ratain MJ J Clin Oncol; 2006 May; 24(15):2221-4. PubMed ID: 16636339 [No Abstract] [Full Text] [Related]
13. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532 [No Abstract] [Full Text] [Related]
15. Targeting resistance in lung cancer. Cancer Discov; 2013 Dec; 3(12):OF9. PubMed ID: 24327718 [No Abstract] [Full Text] [Related]
16. Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know. D'Antonio C; Milano A; Righini R; Onesti CE; Bassanelli M; Falcone R; Paris I; Lauro S; Marchetti P Anticancer Res; 2014 Oct; 34(10):5241-50. PubMed ID: 25275016 [TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim. Couzin J Science; 2004 Aug; 305(5688):1222-3. PubMed ID: 15333809 [No Abstract] [Full Text] [Related]
18. Large personalised medicine trial in lung cancer heralds new research partnership. Torjesen I BMJ; 2014 Apr; 348():g2837. PubMed ID: 24742663 [No Abstract] [Full Text] [Related]